- Home
- BOC vs STRO Comparison
BOC vs STRO Comparison
Compare BOC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOC | STRO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.5M | 332.8M |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BOC | STRO |
|---|---|---|
| Price | $13.03 | $15.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $47.23 |
| AVG Volume (30 Days) | 127.1K | ★ 284.8K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $114,376,348.00 | $38,419,000.00 |
| Revenue This Year | $4.74 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $10.52 | $0.72 |
| 52 Week High | $15.22 | $43.85 |
Technical Indicators
Market Signals| Indicator | BOC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 31.62 |
| Support Level | $12.90 | $14.81 |
| Resistance Level | $13.03 | $17.33 |
| Average True Range (ATR) | 0.30 | 0.92 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 9.27 | 44.34 |
Price Performance
Historical ComparisonAbout BOC Boston Omaha Corporation
Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.